Intended for healthcare professionals

Archive

Patients regain weight rapidly after stopping weight loss drugs – but still keep off a quarter of weight lost

Written by | 11 Mar 2026

A year after stopping taking weight loss drugs such as Ozempic and Wegovy, people regain on average 60% of their lost weight – but beyond this, their weight […]

Findings suggest that certain medications for Type 2 diabetes reduce risk of dementia

Written by | 26 Jan 2026

A large McGill University study has found that two classes of medications commonly prescribed for Type 2 diabetes, both incretin-based, are associated with a reduced risk of dementia. […]

GLP-1s are changing the foods Americans buy

Written by | 5 Jan 2026

When Americans begin taking appetite-suppressing drugs like Ozempic and Wegovy, the changes extend well beyond the bathroom scale. According to new Cornell University research, the medications are associated […]

GLP-1 weight-loss drugs pose hidden risks for young women

Written by | 17 Sep 2025

Women taking popular weight-loss medications during their reproductive years may be unaware of associated risks to pregnancy and unborn babies, warn Flinders University researchers. A new study has […]

Ozempic (and similar medications) may be the new treatment for opioid and alcohol use disorder

Written by | 19 Oct 2024

A new study published in the scientific journal Addiction has found that people with opioid or alcohol use disorder (OUD, AUD) who take Ozempic or similar medications to treat diabetic/weight-related […]

Despite heavy marketing, most Americans reject the new weight-loss drugs

Written by | 10 Oct 2024

A new national survey shows that, despite intense marketing, most Americans do not want the new weight-loss injectables, such as Wegovy and Ozempic. The survey was conducted by Morning Consult […]

Survey shows 25% of adults consider weight loss drug use without prescription

Written by | 23 Sep 2024

Injectable weight loss drugs are popular right now but can be hard to get because they are in short supply or too expensive without insurance. The result is […]

Exploding popularity of Ozempic and Wegovy among privately insured patients may worsen disparities

Written by | 5 Aug 2024

A new USC study suggests that publicly insured individuals who are most likely to benefit from new drugs for diabetes and obesity are less likely to get them than those with […]

EU drug watchdog warns of fake Ozempic pens

Written by | 22 Oct 2023

The European Medicines Agency (EMA) is warning patients and healthcare professionals to beware of pre-filled pens falsely labelled as Ozempic, a diabetes medicine linked to weight loss. National […]

Semaglutide (Ozempic/Wegovy) shows 3-year efficacy for blood sugar control and weight loss

Written by | 5 Oct 2023

Data from a “real world” study indicates that treatment with the semaglutide (Ozempic/Wegovy) for type 2 diabetes significantly improves both blood sugar control and weight loss for up […]

NHS England moves to restrict use of GLP-1 agonists

Written by | 10 Jul 2023

On 27th June 2023 NHS England issued a Medicine Supply Notification (MSN/2023/061) concerning GLP-1 receptor agonists (GLP-1 RAs) used for management of type 2 diabetes. This action has […]

Pharmacy-led obesity management with GLP agonists

Written by | 21 Jun 2023

Deborah Evans is Superintendent Pharmacist and Clinic Director at Remedi Health, where she runs a weight management service, including the provision of semaglutide. In this series of short […]

Newsletter Icon

Sign up to our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare news and e-journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Sign Up

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our email journals and publications.